Full Press Release Details
PureTech Provides End of Year Report on Key Progress
Rapid advancement of PureTech s Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that
demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and proof of principle, oral bioavailability and tolerability for LYT-300 (oral
allopregnanolone). Robust dose escalation and safety data also announced from completed monotherapy portion of Phase 1 program for LYT-200 (anti-galectin-9 mAb)
Catalyst-rich 2023 anticipated, with results from late-stage trial of LYT-100 in idiopathic
pulmonary fibrosis and Phase 1b trial of LYT-200 in leukemia. Initiation of clinical trials planned with LYT-300 and LYT-310
(oral cannabidiol) targeting neurological conditions as well as the combination portion of the Phase 1 trial of LYT-200 in solid tumors
Continued momentum across Founded Entities, including Karuna s positive Phase 3 results for KarXT in schizophrenia, commercial progress
for Gelesis Plenity and Akili s EndeavorRx and Vor s promising initial data in acute myeloid leukemia
Board composition and committee changes also noted
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ( PureTech or the Company ), a clinical-stage biotherapeutics company dedicated to
changing the treatment paradigm for devastating diseases, today reported on the key progress made across its Wholly Owned Programs1 and Founded Entities2 in 2022.
Daphne Zohar, Founder and Chief Executive Officer of PureTech, commented: 2022 has been
a particularly successful and productive year in both crystallizing value and shaping the future of PureTech. Our primary focus is to progress our Wholly Owned Pipeline to commercialization and deliver new classes of medicines for patients with
serious, debilitating conditions. We are advancing toward this goal by deepening our commitment to programs with compelling clinical data that are moving into late-stage studies and that we believe have the potential for broad impact.
Over the next 12 months, we anticipate multiple important catalysts that will further guide how we prioritize our pipeline, informing our decisions
regarding which programs we will drive to commercial launches ourselves and which programs could be most successfully advanced through other avenues such as a partnership, sale, or spinout into another entity.
PureTech s Wholly Owned Programs are centered on developing breakthrough medicines for patients with underserved and serious diseases. The Company s
therapeutic candidates are being advanced for the potential treatment of devastating conditions including idiopathic pulmonary fibrosis (IPF), metastatic solid tumors, leukemia and certain neurological and neuropsychological indications.
Additionally, PureTech s Founded Entities are advancing 20 therapeutics and therapeutic candidates, of
which two (Plenity for weight management3 and EndeavorRx for treating
inattention in ADHD ages 8-124) have received both U.S. FDA clearance and European marketing authorization and a third (KarXT for schizophrenia) will soon
be filed for FDA approval, as of the most recent update by the company. Key highlights include the following:
Key Wholly Owned Program Updates
Key Founded Entity Updates:
Composition & Committee Changes:
Mr. Viehbacher noted: It has been truly
rewarding to work with such a talented group of people who share a genuine passion for helping patients. Together, we have developed a pharmaceutical pioneer delivering innovative medicines with a proven track record that is truly differentiated
across the industry. The foundation for these successes is supported by a strong cash position and unique business model to support continued growth. I m proud of these collective accomplishments and I look forward to continuing to interact
with my colleagues at PureTech in this next exciting phase for the company.
Ms. Zohar commented: For nearly a decade, Chris has brought
a balance of enthusiasm and skepticism to the PureTech Board that is emblematic of our approach. His commercial expertise, deal-making ethos and patient-centered focus have helped to shape our mission and laid the foundation for our future growth. I
am grateful that Chris will remain a trusted advisor, and we wish him much success as he takes the helm at Biogen.
About PureTech Health
PureTech is a biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases. The Company has created a broad and deep
pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech s Founded
Entities, is comprised of 26 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx ) that have received both
U.S. FDA clearance and European marketing authorization and a third (KarXT) that will soon be filed for FDA approval, as of the most recent update by the Company. All of the underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to the Company s
LYT-100 development program and the timing for results from ongoing clinical trials of LYT-100, the LYT-200 development program
and the timing for results from ongoing clinical trials of LYT-200, the planned initiation of clinical trials for LYT-300 and
LYT-310, the potential therapeutic benefits of the product candidates within Company s Wholly Owned Programs, the Company s plan related
to the prioritization of programs and activities associated with its pipeline, the Company s approach to potential partnerships or spinouts of its platforms or candidates and our future
prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and
achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption Risk Factors in our Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies
of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update
or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000